

Synchro VasQ Represents Paradigm Shift in the Treatment of Vascular Lesions



Paolo Bonan, M.D.
Laser Researcher
Professor of Dermatology
University of Florence
Florence, Italy

“The new Synchro VasQ offers great versatility, allowing me to effectively and safely treat a wide-range of aesthetic indications, all from a single platform.”



Scar before Tx



Scar after Synchro VasQ Tx

Photos courtesy of Professor G. Cannarozzo, M.D., Professor P. Campolmi, M.D., and Professor Paolo Bonan, M.D.

By Ilya Petrou, M.D., Contributing Editor

The Synchro VasQ from DEKA (Firenze, Italy), is an innovatively designed platform set to become a gold standard approach for the treatment and management of both deep and superficial vascular lesions such as port-wine stains, hemangiomas, telangiectases and erythrosis.

According to Paolo Bonan, M.D., a laser researcher and professor of dermatology at the University of Florence, Italy, “the new Synchro VasQ offers great versatility, allowing me to effectively and safely treat a wide-range of aesthetic indications, all from a single platform. In my opinion, the device is an intelligent investment and can serve as a good workhorse for many different indications commonly seen in an aesthetic practice.”

Powered by DEKA’s new, state-of-the-art 595 nm selective pulsed dye laser platform, along with a selective pulsed dye lamp handpiece, the Synchro VasQ represents a treatment solution for numerous vascular lesions. The 595 nm wavelength is well absorbed by oxyhemoglobin, making this chosen wavelength ideal for various cutaneous vascular anomalies.

Though standard pulsed dye lasers are commonly used to treat vascular lesions in patients of all Fitzpatrick skin types, treatments are often associated with significant pigmentary and textural complications, raising the need for safer and more effective modalities and approaches. Dr. Bonan has been using the Synchro VasQ for about one year and he, “not only finds the device to be very quick and effective in the treatment of deeper vascular lesions such as port-wine stains, but also ideal for more

superficial vascular lesions such as rosacea and erythrosis.”

DEKA’s unique RightLight™ selective pulsed dye lamp handpiece technology allows physicians to effectively and safely treat superficial aesthetic indications. “Other devices and technologies cannot successfully treat indications such as erythrosis. Furthermore, treatments are typically associated with pain,” Dr. Bonan continued. “In contrast, the Synchro VasQ with RightLight technology provides efficacious treatment of this indication in a very tolerable manner without the generation of purpura, regardless of Fitzpatrick skin type. In my experience, this is the very first time a dye laser can achieve such marked clinical outcomes,” he reported.

Beyond vascular skin lesions, Dr. Bonan said that Synchro VasQ can also be used for other aesthetic indications, achieving significant outcomes in stretch marks and hypertrophic scars, as well as improving the cosmesis of psoriasis, thanks to DEKA’s new high energy emission pulse. This exclusive dye pulse technology offers a wide-range of spot sizes, fluences, pulse durations and peak powers, resulting in more efficient and safer treatments.

In Dr. Bonan’s experience, “the Synchro VasQ is very useful and can achieve great results in hypertrophic scars. For hypertrophic scars and particularly for keloids, I believe it is best to treat using a multi-faceted approach, such as combining the Synchro VasQ with a local steroid injection. This combination approach allows us to decrease the steroid dose which in turn will help reduce the potential risk of atrophy,” he said.